TREM2 and Alzheimer disease: Along with in vitro data showing MS4A-targeting antibodies can induce corresponding alterations in sTREM2, MS4A variants associated with reduced AD risk and delayed dementia onset have been linked to higher TREM2 in plasma and higher sTREM2 in CSF [110, 111].